Drugs / V116517
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02695745 | Sep 2011 → Jan 2012 | — | Purdue Pharma LP | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT01688947 | Sep 2012 → Mar 2014 | postherpetic neuralgia | Purdue Pharma LP | Completed | No outcome recorded |
| Phase 2 | NCT01688934 | Sep 2012 → Jun 2013 | osteoarthritis, knee | Purdue Pharma LP | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | V116517 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01688934 ↗ |
| Route | Oral | “Taken orally twice daily” NCT01688934 ↗ |